MannKind Corporation (Nasdaq: MNKD) today reported financial results for the fourth quarter and year ended December 31, 2011.
For the fourth quarter of 2011, total operating expenses were $30.6 million, compared to $32.1 million for the fourth quarter of 2010, a decrease of $1.5 million. Research and development (R&D) expenses were $20.2 million for the fourth quarter of 2011 compared to $24.2 million for the same quarter in 2010, a decrease of $4.0 million. This 16% decrease was primarily due to the termination of our insulin supply agreement as the Company did not purchase insulin in the current quarter, partially offset by an increase in clinical trial related activities as two clinical trials were initiated in the fourth quarter of 2011. General and administrative (G&A) expenses increased by $2.4 million to $10.3 million for the fourth quarter of 2011 compared to $7.9 million in the fourth quarter of 2010.
The net loss applicable to common stockholders for the fourth quarter of 2011 was $36.4 million, or $0.30 per share based on 122.4 million weighted average shares outstanding, compared with a net loss applicable to common stockholders of $38.3 million, or $0.33 per share based on 114.9 million weighted average shares outstanding for the fourth quarter of 2010. The number of common shares outstanding at December 31, 2011 was 131,522,945.
For the year ended December 31, 2011, total operating expenses were $140.6 million, compared with $152.6 million for 2010, a decrease of $12.0 million. R&D expenses were $100.0 million in 2011, compared to $112.3 million in 2010, a decrease of $12.3 million. The 11% decrease was primarily due to lower purchases of raw materials as a result of the termination of our insulin supply agreement. The final shipment of recombinant human insulin from Organon was received in the third quarter of 2011. Additionally, the Company incurred reduced salary and other compensation expenses as a result of a reduction in force in February 2011. G&A expenses were $40.6 million for 2011 as compared to $40.3 million for 2010.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV